Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073774 | 0.88 | NAMPT (0.50) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL18776391 | 0.86 | ALDH1A1 (0.44) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL23253692 | 0.80 | HCAR3 (0.47) | HCAR3 | |
| SCHEMBL17402077 | 0.80 | HCAR3 (0.45) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL16710813 | 0.79 | HCAR3 (0.45) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL16710920 | 0.77 | EPHX2 (0.48) | RAB9ALMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19130324 | 0.76 | RAB9A (0.51) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL18786346 | 0.74 | RAB9A (0.49) | RAB9ALMNAALDH1A1MAPTGAA | |
| SCHEMBL19033090 | 0.73 | HCAR3 (0.46) | RAB9AMAPTGAASMN1; SMN2HCAR3 | |
| SCHEMBL18073750 | 0.71 | NPC1 (0.47) | RAB9ALMNAALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | RAB9A 3445/4885LMNA 412/4885ALDH1A1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.